Last reviewed · How we verify
NCT05083026
Neutralizing Antibody Level After COVID-19 Vaccination
trial testing COVID-19 neutralizing antibody in Covid19 in 51 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Kyungpook National University Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 51 |
| Start date | 2 June 2021 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- COVID-19 neutralizing antibody
Conditions studied
- Covid19 — all drugs for Covid19 →
Sponsor
Kyungpook National University Hospital
Who can join
Adults 20 to 60, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
1. serial of neutralizing antibody at 2, 4, 6, 9, 12 month after COVID-19 vaccination 2. investigate the factors on antibody titer.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Demographic and Clinical Factors Associated With Anti-SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses.
Nam SY, Jeon SW, Lee HS, Lim HJ, et al · · 2022 · cited 13× · PMID 35587345 · DOI 10.1001/jamanetworkopen.2022.12996 -
Body Weight is Inversely Associated with Anti-SARS-CoV-2 Antibody Levels after BNT162b2 mRNA Vaccination in Young and Middle Aged Adults.
Nam SY, Jeon SW, Jung DK, Heo SJ. · · 2022 · cited 4× · PMID 36196609 · DOI 10.3947/ic.2022.0089
Verify or expand the search:
- PubMed search for NCT05083026
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other Kyungpook National University Hospital trials
Trials by the same sponsor.
- NCT07265817 — Fecal Microbiota Transplantation for Decolonization of Multidrug-resistant Microorganisms · NA · not yet recruiting
- NCT06215040 — The Treatment Effect for Asymptomatic Common Bile Duct Stone · recruiting
- NCT05849324 — Intravascular Injection Rate During Lumbar Transforaminal Epidural Block Using Bent or Straight Needles · NA · unknown
- NCT05046054 — The Effect of Transcutaneous Electrical Nerve Stimulation on Pain During Propofol Injection · NA · unknown
- NCT03426904 — Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer · Phase 3 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05083026 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kyungpook National University Hospital
- Last refreshed: 4 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05083026.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing